Plasma levels of olanzapine: Findings from an open-label study of adolescents and young adults with schizophrenia

被引：0
|
作者：
Dittmann, R [1 ]
Clement, H [1 ]
Knebel, W [1 ]
Roesch, F [1 ]
Hagenah, U [1 ]
Junghanss, J [1 ]
Maestele, A [1 ]
Mehler, C [1 ]
Meyer, C [1 ]
Pitzer, M [1 ]
Remschmidt, H [1 ]
Schlamp, D [1 ]
Schulte-Markwort, M [1 ]
Weiffenbach, O [1 ]
机构：
[1] Lilly Deutschland GmbH, Dept Med, Bad Homburg, Germany
来源：
SCHIZOPHRENIA BULLETIN | 2005年 / 31卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：481 / 481
页数：1
相关论文
共 50 条
  • [31] Olanzapine in Chinese treatment-resistant patients with schizophrenia: An open-label, prospective trial
    Chiu, NY
    Yang, YK
    Chen, PS
    Chang, CC
    Lee, IH
    Lee, JR
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2003, 57 (05) : 478 - 484
  • [32] Olanzapine Added to Roluperidone, in Patients With Schizophrenia and Negative Symptoms, a Safety Open-Label Trial
    Davidson, Michael
    Luthringer, Remy
    Saoud, Jay
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 160 - 160
  • [33] Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine A 2-Year, Randomized, Open-Label Study in Outpatients With Schizophrenia
    Detke, Holland C.
    Weiden, Peter J.
    Llorca, Pierre-Michel
    Choukour, Moutaz
    Watson, Susan B.
    Brunner, Elizabeth
    Ascher-Svanum, Haya
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (04) : 426 - 434
  • [34] OPEN-LABEL COMPARISON OF OLANZAPINE LONG-ACTING INJECTION AND ORAL OLANZAPINE: A 2-YEAR, RANDOMIZED STUDY IN OUTPATIENTS WITH SCHIZOPHRENIA
    Detke, Holland C.
    Weiden, Peter J.
    Llorca, P. M.
    Choukour, M.
    Watson, Susan B.
    Brunner, E.
    Ascher-Svanum, H.
    SCHIZOPHRENIA BULLETIN, 2011, 37 : 300 - 300
  • [35] Olanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients: a 2-year, randomized, open-label study
    Detke, H.
    Weiden, P. J.
    Lambert, T.
    Llorca, P. M.
    Choukour, M.
    Watson, S. B.
    Brunner, E.
    Ascher-Svanum, H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S464 - S464
  • [36] Dose Reduction of Risperidone and Olanzapine and Estimated Dopamine D2 Receptor Occupancy in Stable Patients With Schizophrenia: Findings From an Open-Label, Randomized, Controlled Study
    Takeuchi, Hiroyoshi
    Suzuki, Takefumi
    Bies, Robert R.
    Remington, Gary
    Watanabe, Koichiro
    Mimura, Masaru
    Uchida, Hiroyuki
    JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (11) : 1209 - 1214
  • [37] A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder
    Frazier, JA
    Biederman, J
    Tohen, M
    Feldman, PD
    Jacobs, TG
    Toma, V
    Rater, MA
    Tarazi, RA
    Kim, GS
    Garfield, SB
    Sohma, M
    Gonzalez-Heydrich, J
    Risser, RC
    Nowlin, ZM
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2001, 11 (03) : 239 - 250
  • [38] Olanzapine in the treatment of adolescents with bipolar mania; 26-week open-label extension
    Tohen, Mauricio
    Kryzhanovskaya, Ludmila
    Carlson, Gabrielle
    DelBello, Melissa
    Wozniak, Janet
    Kowatch, Robert
    Wagner, Karen
    Findling, Robert
    Lin, Daniel
    Robertson-Plouch, Carol
    Xu, Wen
    Dittman, Ralf
    Biederman, Joe
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2007, 17 (06) : 882 - 882
  • [39] AN OPEN-LABEL STUDY OF FAMOTIDINE AS A TREATMENT FOR SCHIZOPHRENIA - REPLY
    OYEWUMI, LK
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 1995, 20 (03): : 240 - 240
  • [40] Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
    Miyaoka, Tsuyoshi
    Yasukawa, Rei
    Yasuda, Hideaki
    Hayashida, Maiko
    Inagaki, Takuji
    Horiguchi, Jun
    CLINICAL NEUROPHARMACOLOGY, 2008, 31 (05) : 287 - 292
12345